NCT05479552 - A Diagnostic Test for Dementia With Lewy Bodies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 15, 2022

Primary Completion Date

September 28, 2025

Study Completion Date

October 31, 2025

Conditions

MCI-AD, Early Stage Alzheimer's DiseaseMCI-DLB, Early Stage Dementia With Lewy Bodies

Interventions

DIAGNOSTIC_TEST

Syn-One Test

CND Life Sciences is expanding the utility of its diagnostic technology, the Syn-One Test, to pathologically distinguish between early DLB and Alzheimer's disease to prevent misdiagnoses and establish the relationship between progression and α-synuclein deposition by measuring α- synuclein accumulation in patient's nerve fibers using a simple skin punch biopsy.

Trial Locations (12)

32792

Neurology One, Winter Park

33433

University of Miami, Boca Raton

37240

Vanderbilt University Medical Center, Nashville

48105

University of Michigan, Ann Arbor

70121

Ochsner Research, New Orleans

80113

CenExel RMCR, Englewood

84108

University of Utah, Salt Lake City

85258

CND Life Sciences, Scottsdale

92037

University of California San Diego, La Jolla

02145

Mass General Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

02360

Headlands Research, Plymouth